CRVO

Company Overview — What Does CervoMed Inc. Do?

CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of drug treatments for neurodegenerative diseases. It develops neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, and brain stroke recovery. The company is based in Boston, Massachusetts. CervoMed Inc. (CRVO) is classified as a micro-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO John J. Alam and employs approximately 4 people, headquartered in CHARLOTTESVILLE, Massachusetts. With a market capitalization of $37M, CRVO is one of the notable companies in the Healthcare sector.

CervoMed Inc. (CRVO) Stock Rating — Avoid (April 2026)

As of April 2026, CervoMed Inc. receives a Avoid rating with a composite score of 23.2/100 and 1 out of 5 stars from the Blank Capital Research quantitative model.CRVO ranks #4,161 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, CervoMed Inc. ranks #734 of 838 stocks, placing it in the lower half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

CRVO Stock Price and 52-Week Range

CervoMed Inc. (CRVO) currently trades at $3.83. The stock lost $0.20 (5.0%) in the most recent trading session. The 52-week high for CRVO is $16.94, which means the stock is currently trading -77.4% from its annual peak. The 52-week low is $3.58, putting the stock 7.0% above its annual trough. Recent trading volume was 35K shares, suggesting relatively thin trading activity.

Is CRVO Overvalued or Undervalued? — Valuation Analysis

CervoMed Inc. (CRVO) carries a value factor score of 12/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 1.95x, versus the sector average of 2.75x. The price-to-sales ratio is 5.99x, compared to 1.66x for the average Healthcare stock.

At current multiples, CervoMed Inc. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

CervoMed Inc. Profitability — ROE, Margins, and Quality Score

CervoMed Inc. (CRVO) earns a quality factor score of 20/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -129.7%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -103.3% versus the sector average of -33.1%.

On a margin basis, CervoMed Inc. reports gross margins of 100.0%, compared to 71.5% for the sector. The operating margin is -856.2% (sector: -66.1%). Net profit margin stands at -812.9%, versus -58.7% for the average Healthcare stock. Revenue growth is running at -90.2% on a trailing basis, compared to 10.6% for the sector. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

CRVO Debt, Balance Sheet, and Financial Health

CervoMed Inc. has a debt-to-equity ratio of 26.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. The current ratio is 4.91x, indicating strong short-term liquidity. Total debt on the balance sheet is $0. Cash and equivalents stand at $9M.

CRVO has a beta of 0.95, meaning it is roughly in line with the broader market in terms of price volatility. The stability factor score for CervoMed Inc. is 26/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

CervoMed Inc. Revenue and Earnings History — Quarterly Trend

In TTM 2026, CervoMed Inc. reported revenue of $6M and earnings per share (EPS) of $-2.98. Net income for the quarter was $-24M. Gross margin was 100.0%. Operating income came in at $-25M.

In FY 2025, CervoMed Inc. reported revenue of $4M and earnings per share (EPS) of $-2.98. Net income for the quarter was $-27M. Revenue grew -58.9% year-over-year compared to FY 2024. Operating income came in at $-28M.

In Q3 2025, CervoMed Inc. reported revenue of $322,569 and earnings per share (EPS) of $-0.84. Net income for the quarter was $-8M. Revenue grew -83.4% year-over-year compared to Q3 2024. Operating income came in at $-8M.

In Q2 2025, CervoMed Inc. reported revenue of $2M and earnings per share (EPS) of $-0.70. Net income for the quarter was $-6M. Revenue grew -46.6% year-over-year compared to Q2 2024. Operating income came in at $-7M.

Over the past 8 quarters, CervoMed Inc. has demonstrated a growth trajectory, with revenue expanding from $3M to $6M. Investors analyzing CRVO stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

CRVO Dividend Yield and Income Analysis

CervoMed Inc. (CRVO) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

CRVO Momentum and Technical Analysis Profile

CervoMed Inc. (CRVO) has a momentum factor score of 11/100, signaling weak relative price performance. Stocks with low momentum scores have historically tended to continue underperforming in the near term. The investment factor score is 40/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 61/100 reflects moderate short selling activity.

CRVO vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, CervoMed Inc. (CRVO) ranks #734 out of 838 stocks based on the Blank Capital composite score. This places CRVO in the lower half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing CRVO against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full CRVO vs S&P 500 (SPY) comparison to assess how CervoMed Inc. stacks up against the broader market across all factor dimensions.

CRVO Next Earnings Date

No upcoming earnings date has been announced for CervoMed Inc. (CRVO) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy CRVO? — Investment Thesis Summary

The quantitative profile for CervoMed Inc. suggests caution. The quality score of 20/100 flags below-average profitability. The value score of 12/100 indicates premium valuation. Momentum is weak at 11/100, a headwind for near-term performance. High volatility (stability score 26/100) increases portfolio risk.

In summary, CervoMed Inc. (CRVO) earns a Avoid rating with a composite score of 23.2/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on CRVO stock.

Related Resources for CRVO Investors

Explore more research and tools: CRVO vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare CRVO head-to-head with peers: CRVO vs AZN, CRVO vs SLGL, CRVO vs VMD.